Global Intranasal Drug Delivery Device Market Size By Type (Multidose, Uni/bidose), By Application (Personal Use, Hospital Use), By Region, And Segment Forecasts, 2023 to 2032

The Global Intranasal Drug Delivery Device Market was valued at USD 7.3 billion in 2023 and is projected to reach USD 13.4 billion by 2031, growing at a CAGR of 7.8% during the forecast period from 2023 to 2031. The increasing demand for non-invasive and patient-friendly drug administration methods is significantly propelling market growth. Intranasal drug delivery devices offer rapid onset of action, enhanced patient compliance, and bypass first-pass metabolism—making them a preferred choice for delivering vaccines, pain relievers, and treatments for central nervous system (CNS) disorders. With advancements in formulation technology and the rise in self-administration trends, the intranasal drug delivery device market is witnessing robust adoption globally.

Drivers:

1. Rising Preference for Non-Invasive Drug Delivery:

Patients and healthcare providers are increasingly shifting toward non-invasive drug delivery systems due to ease of use, reduced risk of infection, and improved comfort. Intranasal devices fit this trend, offering effective administration without the need for needles.

2. Growth in CNS and Pain Management Therapeutics:

Intranasal drug delivery is extensively used for CNS disorders such as migraines, epilepsy, and Parkinson’s disease, owing to its ability to quickly deliver drugs to the brain through the olfactory region. The rising incidence of these conditions is accelerating demand.

3. Technological Advancements in Device Design:

The development of precision-engineered nasal sprays and atomizers that enhance drug absorption and minimize dosing errors is a key driver. Innovative designs that support single-use and multi-dose applications are broadening clinical use cases.

Restraints:

1. Limited Drug Formulation Suitability:

Not all pharmaceutical compounds are suitable for nasal delivery due to size, solubility, or irritation potential, which restricts the broader applicability of intranasal drug delivery systems.

2. Nasal Mucosal Irritation and Compliance Issues:

Prolonged or frequent use of intranasal devices can cause irritation or damage to the nasal mucosa, affecting patient adherence. Additionally, variability in absorption due to individual nasal physiology can impact drug efficacy.

Opportunity:

1. Expansion in Emergency and Pandemic Applications:

Intranasal devices are increasingly explored for emergency treatments (e.g., naloxone for opioid overdose) and vaccines, especially in pandemic situations where rapid and mass administration is needed. This represents a high-growth opportunity for market players.

2. Growing Acceptance of Self-Administration:

The surge in at-home healthcare and chronic disease management has increased the demand for user-friendly devices that allow patients to self-administer medications, further expanding market potential.

Market by System Type Insights:

Based on system type, the multi-dose nasal spray devices segment led the market in 2023. These systems offer convenience and are widely used in chronic therapies, particularly for allergic rhinitis and migraine treatments. Meanwhile, unit-dose spray devices are gaining momentum, especially for emergency applications like seizure intervention and opioid overdose, where rapid and precise delivery is critical.

Market by End-use Insights:

In terms of end use, the hospital and clinics segment accounted for the largest share in 2023. These settings handle acute conditions requiring rapid medication delivery. However, the home care settings segment is anticipated to witness the fastest growth, driven by patient preference for self-care and advancements in device automation and safety.

Market by Regional Insights:

Geographically, North America dominated the global intranasal drug delivery device market in 2023 due to the region’s strong healthcare infrastructure, high adoption of advanced drug delivery technologies, and prevalence of respiratory and CNS conditions. Asia-Pacific is expected to experience the highest growth rate, fueled by rising healthcare expenditure, growing awareness of non-invasive therapies, and supportive regulatory frameworks in countries like China, India, and Japan.

Competitive Scenario:

Key players in the Global Intranasal Drug Delivery Device Market include:

AptarGroup, Inc.

Kurve Technology, Inc.

OptiNose, Inc.

Nemera

Becton, Dickinson and Company (BD)

3M Company

Teleflex Incorporated

Pfizer Inc.

GlaxoSmithKline plc

AstraZeneca plc

These companies are actively investing in R&D, strategic partnerships, and regional expansions. For instance:

In 2023, OptiNose announced the clinical trial success of its precision delivery platform targeting migraine relief.

Kurve Technology launched a new nasal nebulizer in 2024 designed for higher bioavailability and improved CNS targeting.

AptarGroup expanded its manufacturing capabilities in 2025 to meet the increasing demand for nasal spray components in emergency medicine.

Scope of Work – Global Intranasal Drug Delivery Device Market

Report Metric Details

Market Size (2023) USD 7.3 billion

Projected Market Size (2031) USD 13.4 billion

CAGR (2023–2031) 7.8%

Market Segments By System Type (Unit-Dose, Multi-Dose, Pressurized Metered-Dose), By End-use (Hospitals & Clinics, Home Care Settings, Others), By Region

Growth Drivers Rising preference for non-invasive delivery, surge in CNS and pain treatments, and device innovation

Opportunities Emergency drug use, pandemic vaccinations, and growth in self-administered therapies

Key Market Developments:

2023: OptiNose initiated Phase III trials for a new nasal delivery treatment for cluster headaches.

2024: Kurve Technology unveiled an updated Breath Powered delivery system for neurological drug applications.

2025: AptarGroup, Inc. formed a strategic alliance with a global pharma firm to develop nasal delivery platforms for mRNA vaccines.

FAQs:

1) What is the current market size of the Global Intranasal Drug Delivery Device Market?

The market was valued at USD 7.3 billion in 2023.

2) What is the major growth driver of the Global Intranasal Drug Delivery Device Market?

The primary driver is the rising preference for non-invasive drug delivery and rapid onset of action for CNS and emergency treatments.

3) Which is the largest region during the forecast period in the Global Intranasal Drug Delivery Device Market?

North America holds the largest market share due to advanced healthcare systems and high technology adoption.

4) Which segment accounted for the largest market share in the Global Intranasal Drug Delivery Device Market?

The multi-dose nasal spray devices segment held the largest share in 2023.

5) Who are the key market players in the Global Intranasal Drug Delivery Device Market?

AptarGroup, OptiNose, Kurve Technology, 3M Company, BD, Teleflex, and others are among the key players.

Let me know if you'd like a visual report or exportable format (PDF, DOCX) as well!